A flow cytometric approach to compare stem cell apoptosis in aplastic anemia and hypoplastic myelodysplastic syndrome.

Autor:	Ibrahim M; Department of Food Science, University of Guelph, Guelph, Canada., Khodeary A; Department of Clinical Pathology, Faculty of Medicine, Sohag University, Sohag, Egypt., Aziz SP; Department of Clinical Pathology, Faculty of Medicine, Sohag University, Sohag, Egypt., Mahmoud MG; Department of Internal Medicine, Faculty of Medicine, Sohag University, Sohag, Egypt., Abdel-Baset AA; Department of Internal Medicine, Faculty of Medicine, Sohag University, Sohag, Egypt., Mohamed T; Department of Medical Microbiology and Immunology, Faculty of Medicine, Sohag University, Sohag, Egypt., Sayed SA; Department of Clinical Pathology, Faculty of Medicine, Sohag University, Sohag, Egypt.
Jazyk:	angličtina
Zdroj:	Hematology/oncology and stem cell therapy [Hematol Oncol Stem Cell Ther] 2024 Jul-Sep 01; Vol. 17 (3), pp. 184-189. Date of Electronic Publication: 2024 Oct 04.
DOI:	10.4103/hemoncstem.HEMONCSTEM-D-24-00008
Abstrakt:	Background and Objectives: Aplastic anemia (AA) is a disease caused by bone marrow (BM) failure. There are many similarities between AA and hypoplastic myelodysplastic syndrome (MDS); hence, differentiating them could be problematic. The current study aimed to use the new technique of flow cytometry as a possible diagnostic tool for AA and hypoplastic MDS. Patients and Methods: The BM mononuclear cell (BMMC) and blood samples from 44 participants (17 patients with AA, 13 with hypoplastic MDS, and 14 healthy controls) were collected. The flow cytometric analysis of the cluster of differentiation 34 (CD34) levels and cell apoptosis was performed for all sample types. Results: Patients with hypoplastic MDS showed a high percentage of CD34+ cells with low apoptosis, while those with AA showed a low percentage of CD34+ cells with high apoptosis. Conclusions: Despite the similarity in the clinical presentation of hypoplastic MDS and AA, they are biologically different disorders. Increased CD34+ cell numbers with high viability may provide a useful and accurate tool for the differential diagnosis of hypoplastic MDS from AA. (Copyright © 2024 Hematology/Oncology and Stem Cell Therapy.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu